(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
12 July 2012 (12.07.2012)

WIPO | PCT

(10) International Publication Number
WO 2012/094636 A2

(51) International Patent Classification:

A61K 31/4709 (2006.01)	*A61P 3/04* (2006.01)
A61K 31/704 (2006.01)	*A61P 3/00* (2006.01)
A61K 31/7016 (2006.01)	*A61P 3/10* (2006.01)
A61K 31/198 (2006.01)	*A61P 19/10* (2006.01)
A61K 31/201 (2006.01)	*A61P 21/00* (2006.01)
A61K 31/353 (2006.01)	*A61P 37/00* (2006.01)
A61K 31/155 (2006.01)	*A61P 1/00* (2006.01)
A61K 31/7032 (2006.01)	*A61P 25/24* (2006.01)
A61K 31/194 (2006.01)	*A61P 25/22* (2006.01)
A61K 31/575 (2006.01)	*A61P 25/00* (2006.01)
A61P 7/12 (2006.01)	*A61K 31/20* (2006.01)

(21) International Application Number:
PCT/US2012/020548

(22) International Filing Date:
6 January 2012 (06.01.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/430,914 7 January 2011 (07.01.2011) US

(71) Applicant *(for all designated States except US)*: **ELCELYX THERAPEUTICS, INC.** [US/US]; 11995 El Camino Real, Suite 305, San Diego, CA 92130 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BARON, Alain D.** [US/US]; 12863 Baywind Point, San Diego, CA 92130 (US). **BROWN, Martin R.** [US/US]; 834 Tolita Avenue, Coronado, CA 92118 (US). **JONES, Christopher R. G.** [US/US]; 13713 Freeport Road, San Diego, CA 92129 (US). **BEELEY, Nigel R. A.** [US/US]; 227 Loma Corta Drive, Solana Beach, CA 92075 (US). **FINEMAN, Mark S.** [US/US]; 12444 Oakfort Place, San Diego, CA 92130 (US).

(74) Agent: **GUISE, Jeffrey W.**; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, CA 94304-1050 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

(54) Title: CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES




FIG. 1

AUC 27% Difference
p=0.14

AUC 89% Difference
p=0.07

(57) Abstract: Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a chemosensory receptor ligand, such as a bitter receptor ligand. Also provided herein are chemosensory receptor ligand compositions, including bitter receptor ligand compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.

WO 2012/094636 A2